AcelRx Pharmaceuticals, Inc. (ACRX)

Market Cap	31.59M
Revenue (ttm)	2.88M
Net Income (ttm)	45.70M
Shares Out	147.33M
EPS (ttm)	0.30
PE Ratio	0.71
Forward PE	1.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	685,032
Open	0.210
Previous Close	0.207
Day's Range	0.208 - 0.225
52-Week Range	0.160 - 1.080
Beta	0.27
Analysts	Buy
Price Target	4.08 (+1,803.0%)
Earnings Date	Nov 14, 2022

About ACRX

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 ...

• Industry: Pharmaceuticals
• IPO Date: Feb 14, 2011
• CEO: Vincent Angotti
• Employees: 43
• Stock Exchange: NASDAQ
• Ticker Symbol: ACRX

Full Company Profile

Financial Performance

In 2021, ACRX's revenue was $2.82 million, a decrease of -47.97% compared to the previous year's $5.42 million. Losses were -$35.10 million, -13.08% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ACRX stock is "Buy." The 12-month stock price forecast is 4.08, which is an increase of 1,802.99% from the latest price.

Price Target

$4.08

(1,802.99% upside)

Analyst Consensus: Buy

Stock Forecasts